Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
NBTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $10.59
Previous CloseN/A
Volume23.08K
Average Volume (3M)13.85K
Market Cap
$410.80M
Enterprise ValueN/A
Total Cash (Recent Filing)$49.74M
Total Debt (Recent Filing)$50.90M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Sep 04, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,943,150
10 Day Avg. Volume26,484
30 Day Avg. Volume13,847
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside-11.01% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ResearchThe initial results from the MD Anderson collaboration showed a promising 1-year overall survival rate of 83% in patients with locoregional recurrent NSCLC, comparing favorably to the historical control for re-irradiation.
Financial StabilityA recent amendment of its licensing agreement with JNJ extends the company's cash runway to mid-2026, safeguarding the company's path through the interim analysis of the NANORAY-312 trial.
Partnerships And CollaborationsThe partnership with JNJ and the ongoing collaboration are seen as supportive, enhancing the credibility and potential success of NBTXR3.
Bears Say
Financial ConcernsInvestor focus is expected to remain on the company's cash runway and ongoing concerns about the balance sheet, implying financial stability is a key concern for stakeholders.
Financing StrategiesManagement reiterated that it is actively exploring non-dilutive financing options to further extend its runway into 2027.
Nanobiotix News
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $2.76 and its highest was $10.59 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $410.80M.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Sep 04, 2025 which is in 6 days.
How were Nanobiotix’s earnings last quarter?
Currently, no data Available
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Overvalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.35.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,943,150 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
Nanobiotix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (-11.01% Downside)
$8.00 (-11.01% Downside)
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.24%
12-Months-Change
Fundamentals
Return on Equity
2152.93%
Trailing 12-Months
Asset Growth
110.74%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix (NBTX) is a biotechnology company that specializes in the development of nanomedicine products to improve the efficacy of cancer treatments. Founded in 2003 and headquartered in Paris, France, the company focuses on leveraging its proprietary nanotechnology platform to enhance the efficacy of radiotherapy for the treatment of cancer. Nanobiotix's core product is NBTXR3, a first-in-class radioenhancer that is designed to improve the effectiveness of radiotherapy without increasing the dose delivered to surrounding healthy tissue.
NBTX Company Deck
NBTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic progress with the JNJ collaboration and pipeline advancements, along with a strong financial strategy to extend cash runway. However, financial performance showed challenges with negative revenue and increased net loss.View all NBTX earnings summariesNBTX Stock 12 Month Forecast
Average Price Target
$8.00
▼(-11.01% Downside)
Technical Analysis
Sangamo Biosciences
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Molecular Partners
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
11.73% Other Institutional Investors
88.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---